Century Therapeutics FY2022 net loss $130.9M; cash runway extended into 2026

Century Therapeutics, Inc.

Net loss of $130.9M for FY2022 vs $95.8M in FY2021; R&D expenses $97.2M (up 29%).
Cash, cash equivalents, and investments: $367.4M as of Dec 31, 2022; cash runway into 2026.
Collaboration revenue from BMS: $5.2M for FY2022.
Phase 1 ELiPSE-1 trial of CNTY-101 dosed first patient in Feb 2023; initial data by year-end 2023.
FY2023 GAAP operating expense guidance: $135M-$145M, incl. $12M-$17M stock-based comp.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Century Therapeutics, Inc. reported the full-year ended December 31, 2022 results: revenue $5.2 million, net income $130.9 million. Guidance reaffirmed.

Period: the full-year ended December 31, 2022
Revenue: $5.2 million
Net income: $130.9 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

of $118.0 million), compared to net cash used in operations of $89.0 million for the twelve months ended December 31, 2021. · Collaboration Revenue: Collaboration revenue was $5.2 million for the twelve months ended December 31, 2022, generated through the Company’s collaboration, option and license agreement with BMS. · Research and Development (R&D) expenses :

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-033066

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.